ANDA Approval Whiplash: Strong April Follows Terrible March
This article was originally published in The Pink Sheet Daily
Executive Summary
Picture still seems pretty grim, but FDA points to progress on several metrics.
You may also be interested in...
FDA Generics Office To Be Managed By Relative Unknown
Director Uhl’s medical leave puts bioequivalence office head John Peters in the limelight.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?
EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.